Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses

CB-011 is an off-the-shelf, allogeneic CAR-T cell therapy targeting BCMA (B-cell Maturation Antigen), engineered with Caribou's chRDNA genome-editing platform. In short, the chRDNA platform combines CRISPR-Cas genome editing with a proprietary chimeric DNA-RNA guide design that is intended to improve editing precision and reduce off-target activity compared with conventional guide RNAs. CRISPR-Cas editing underpins an immune cloaking strategy in which a B2M knockout is combined with insertion of a B2M-HLA-E-peptide fusion protein, intended to blunt immune-mediated rejection of donor-derived cells.

In the dose escalation portion of the CaMMouflage phase 1 trial, 48 patients were treated with CB-011. The 12 BCMA-naïve patients receiving the recommended expansion dose of 450 million cells – with a median follow up of 17.7 months – showed a 92% overall response rate, an 83% complete response rate, and 91% minimal residual disease negativity, with half remaining in at least complete response at 15 months. The reported safety profile was manageable, with no graft-versus-host disease and one treatment-related death across the broader treated cohort.

A separately presented case study described a 71-year-old patient, previously given eight lines of therapy including ciltacabtagene autoleucel, who reached an ongoing complete response after a single CB-011 infusion.

The data were presented on 14 June 2026 at the European Hematology Association (EHA) Annual Meeting in Stockholm, Sweden and published in a press release on 11 June 2026.

Access the CMN Trials Database here.